Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker NKTR
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 10, 2026 | SCHEDULE 13G | NKTR Nektar Therapeutics | State Street Corporation | 1.77M | 5.2% | SCHEDULE 13G ↗ |
| Sep 28, 2026 | SCHEDULE 13G/A (amended) | NKTR Nektar Therapeutics | Sina Toussi | 3.35M | 9.8% | SCHEDULE 13G/A ↗ |
| Sep 28, 2026 | SCHEDULE 13G/A (amended) | NKTR Nektar Therapeutics | Two Seas Capital GP LLC | 3.35M | 9.8% | SCHEDULE 13G/A ↗ |
| Sep 28, 2026 | SCHEDULE 13G/A (amended) | NKTR Nektar Therapeutics | Two Seas Capital LP | 3.35M | 9.8% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | NKTR Nektar Therapeutics | Sina Toussi | 3.09M | 9.1% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | NKTR Nektar Therapeutics | Two Seas Capital GP LLC | 3.09M | 9.1% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | NKTR Nektar Therapeutics | Two Seas Capital LP | 3.09M | 9.1% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | NKTR Nektar Therapeutics | Mark N. Lampert | 2.39M | 7.1% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | NKTR Nektar Therapeutics | BVF Inc/Il | 2.39M | 7.1% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | NKTR Nektar Therapeutics | BVF Partners L P/Il | 2.39M | 7.1% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | NKTR Nektar Therapeutics | BVF GP Holdings LLC | 2.20M | 6.5% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | NKTR Nektar Therapeutics | BVF Partners OS Ltd. | 157,488 | 0.5% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | NKTR Nektar Therapeutics | Biotechnology Value Trading Fund OS LP | 157,488 | 0.5% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | NKTR Nektar Therapeutics | BVF II GP LLC | 945,732 | 2.8% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | NKTR Nektar Therapeutics | Biotechnology Value Fund II LP | 945,732 | 2.8% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | NKTR Nektar Therapeutics | BVF I GP LLC | 1.25M | 3.7% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | NKTR Nektar Therapeutics | Biotechnology Value Fund L P | 1.25M | 3.7% | SCHEDULE 13G/A ↗ |
| Jul 31, 2026 | SCHEDULE 13G | NKTR Nektar Therapeutics | Vanguard Capital Management | 1.75M | 5.2% | SCHEDULE 13G ↗ |
| Jul 29, 2026 | SCHEDULE 13G | NKTR Nektar Therapeutics | BlackRock, Inc. | 2.64M | 7.8% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | NKTR Nektar Therapeutics | Mark N. Lampert | 2.85M | 9.8% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | NKTR Nektar Therapeutics | BVF Inc/Il | 2.85M | 9.8% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | NKTR Nektar Therapeutics | BVF Partners L P/Il | 2.85M | 9.8% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | NKTR Nektar Therapeutics | BVF GP Holdings LLC | 2.64M | 9.1% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | NKTR Nektar Therapeutics | BVF Partners OS Ltd. | 171,769 | 0.6% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | NKTR Nektar Therapeutics | Biotechnology Value Trading Fund OS LP | 171,769 | 0.6% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | NKTR Nektar Therapeutics | BVF II GP LLC | 1.11M | 3.9% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | NKTR Nektar Therapeutics | Biotechnology Value Fund II LP | 1.11M | 3.9% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | NKTR Nektar Therapeutics | BVF I GP LLC | 1.52M | 5.3% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | NKTR Nektar Therapeutics | Biotechnology Value Fund L P | 1.52M | 5.3% | SCHEDULE 13G/A ↗ |
| May 6, 2026 | SCHEDULE 13G/A (amended) | NKTR Nektar Therapeutics | Abigail P. Johnson | 4.30M | 15.0% | SCHEDULE 13G/A ↗ |
| May 6, 2026 | SCHEDULE 13G/A (amended) | NKTR Nektar Therapeutics | FMR LLC | 4.30M | 15.0% | SCHEDULE 13G/A ↗ |
| Apr 17, 2026 | SCHEDULE 13G | NKTR Nektar Therapeutics | Sina Toussi | 1.96M | 6.8% | SCHEDULE 13G ↗ |
| Apr 17, 2026 | SCHEDULE 13G | NKTR Nektar Therapeutics | Two Seas Capital GP LLC | 1.96M | 6.8% | SCHEDULE 13G ↗ |
| Apr 17, 2026 | SCHEDULE 13G | NKTR Nektar Therapeutics | Two Seas Capital LP | 1.96M | 6.8% | SCHEDULE 13G ↗ |
| Mar 27, 2026 | SCHEDULE 13G/A (amended) | NKTR Nektar Therapeutics | The Vanguard Group | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Mar 6, 2026 | SCHEDULE 13G | NKTR Nektar Therapeutics | Abigail P. Johnson | 3.04M | 11.1% | SCHEDULE 13G ↗ |
| Mar 6, 2026 | SCHEDULE 13G | NKTR Nektar Therapeutics | FMR LLC | 3.04M | 11.1% | SCHEDULE 13G ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | NKTR Nektar Therapeutics | Susquehanna Securities, LLC | 809,967 | 4.0% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | NKTR Nektar Therapeutics | Susquehanna Portfolio Strategies, LLC | 809,967 | 4.0% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | NKTR Nektar Therapeutics | G1 Execution Services, LLC | 809,967 | 4.0% | SCHEDULE 13G/A ↗ |
| Jan 30, 2026 | SCHEDULE 13G | NKTR Nektar Therapeutics | The Vanguard Group | 1.03M | 5.0% | SCHEDULE 13G ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | NKTR Nektar Therapeutics | Chen Yu | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | NKTR Nektar Therapeutics | TCG Crossover Fund II, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | NKTR Nektar Therapeutics | TCG Crossover GP II, LLC | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | NKTR Nektar Therapeutics | Daniel Mack | 418,522 | 2.2% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | NKTR Nektar Therapeutics | Wilmot B. Harkey | 418,522 | 2.2% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | NKTR Nektar Therapeutics | Nantahala Capital Management, LLC | 418,522 | 2.2% | SCHEDULE 13G/A ↗ |
| Nov 13, 2025 | SCHEDULE 13G | NKTR Nektar Therapeutics | Susquehanna Securities, LLC | 1.24M | 6.3% | SCHEDULE 13G ↗ |
| Nov 13, 2025 | SCHEDULE 13G | NKTR Nektar Therapeutics | Susquehanna Portfolio Strategies, LLC | 1.24M | 6.3% | SCHEDULE 13G ↗ |
| Oct 31, 2025 | SCHEDULE 13G/A (amended) | NKTR Nektar Therapeutics | The Vanguard Group | 948,647 | 5.0% | SCHEDULE 13G/A ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 7:12 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances